Eden Biodesign and Selexis Announce Continued Cooperation and a Global Joint-Marketing Collaboration
Collaboration Offers A Powerful Combination of High Productivity Cell Line Development and cGMP Production Services
Liverpool, UK; RTP, NC, USA; Geneva, Switzerland, Boston, MA, USA - June 17, 2009
Eden Biodesign Ltd. and Selexis SA today jointly announced their continued collaboration via a joint-marketing partnership, which will provide global biopharmaceutical companies easy access to their highly complementary services, and the opportunity to drastically reduce timelines and risk for development of monoclonal antibodies and recombinant proteins derived from mammalian cell culture.
Eden Biodesign is UK- and USA-based, globally-integrated provider of biopharmaceutical and vaccine process development and cGMP manufacturing services. The company’s clients also benefit from a range of consultancy services.
Selexis SA is a Swiss-based and USA-based biotechnology company that offers technologies and services for the rapid development of high-performance, stable mammalian cell lines.
Working with global clients, Selexis offers contract development and maintenance of high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. membrane receptors, MAbs, plasma proteins, rProteins in general). The company's technology platform is based on a combination of Intellectual Property (Genetic Elements and transfection procedures) and Know-how (mammalian cell culturing and mammalian cell line screening) around the generation of stable and high producing mammalian cells. Using the Selexis SURE Cell Line Development℠ Platform, the Selexis team offers unmatched speed in the generation of high producing cell lines (5 weeks).
Also working on a global scale, Eden Biodesign offers consultancy and a comprehensive range of biopharmaceutical design, process development and cGMP manufacturing services.
The companies have an established track record of collaboration on a number of client projects. This experience allows new clients to access Selexis’ capabilities for development of highly productive, stable mammalian cell lines before transferring candidates or mini-pools to Eden Biodesign for further screening and selection, process development, and cGMP production. The companies have demonstrated success in working together to significantly accelerate “time to clinic.” The collaboration will be marketed on a global scale by the joint efforts of the companies.
“We are very happy to be able to formally announce our relationship with Selexis and their extremely powerful approach to the development of high-productivity cell lines, which we are able to offer to our clients,” said Dr. Roger Lias, President of Eden Biodesign’s US subsidiary and group commercial director. “We recognize the vital importance of speed-of-development and of attractive final cost-of-goods for biopharmaceuticals. Working with our colleagues at Selexis provides the opportunity for our mutual clients to achieve both.”
“The relationship with Eden has enabled a number of mutual clients the ability to progress rapidly from DNA to cGMP manufacturing with a cost effective manufacturing platform, without sacrificing performance or quality,” said Mr. Andrew Sandford, Vice President of Business Development for Selexis’ US subsidiary. At Selexis we appreciate the efforts associated with cGMP manufacturing and are pleased to recommend Eden to our clients as an ideal option for cGMP manufacturing.”
About Selexis
Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements™ using the SURE Cell Line Development℠ process has enabled the rapid development of high-performance cell lines for a number of pharmaceutically important programs.
About Eden Biodesign
Eden Biodesign is a globally-integrated biopharmaceutical company offering consultancy, biopharmaceutical design and cGMP manufacturing services to leading biotech and pharmaceutical clients around the world. With a reputation for successfully commercializing biopharmaceutical products and processes, the Company offers expertise and guidance in multiple sectors. Eden’s world-class facilities and knowledge in process development, manufacturing, regulatory and technology transfer support ensures Eden Biodesign offers much more than a traditional CMO. Learn more at www.EdenBiodesign.com.
Media Contacts:
Eden Biodesign
John D. Wagner
Propel Marketing Group
919 796 9984
e-mail: Jdwagner@PropelMG.com
www.PropelMG.com
Selexis Corporate Communications
T +41 (0)22 308 93 60
e-mail: info@selexis.com